Subscribe to Journal
Get full journal access for 1 year
only $21.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Durrheim, D. N. et al. A dangerous measles future looms beyond the COVID-19 pandemic. Nat. Med. 27, 360–361 (2021). https://doi.org/10.1038/s41591-021-01237-5.
Hashiguchi, T. et al. Structures of the prefusion form of measles virus fusion protein in complex with inhibitors. Proc. Natl Acad. Sci. USA 115, 2496–2501 (2018).
Tatsuo, H., Ono, N., Tanaka, K. & Yanagi, Y. SLAM (CDw150) is a cellular receptor for measles virus. Nature 406, 893–897 (2000).
Chang, A. & Dutch, R. E. Paramyxovirus fusion and entry: multiple paths to a common end. Viruses 4, 613–636 (2012).
Harrison, S. C. Viral membrane fusion. Nat. Struct. Mol. Biol. 15, 690–698 (2008).
Welsch, J. C. et al. Fatal measles virus infection prevented by brain-penetrant fusion inhibitors. J. Virol. 87, 13785–13794 (2013).
Malvoisin, E. & Wild, F. Contribution of measles virus fusion protein in protective immunity: anti-F monoclonal antibodies neutralize virus infectivity and protect mice against challenge. J. Virol. 64, 5160–5162 (1990).
Fayolle, J., Verrier, B., Buckland, R. & Wild, T. F. Characterization of a natural mutation in an antigenic site on the fusion protein of measles virus that is involved in neutralization. J. Virol. 73, 787–790 (1999).
Avila, M. et al. Molecular determinants defining the triggering range of prefusion F complexes of canine distemper virus. J. Virol. 88, 2951–2966 (2014).
Czuppon, P. et al. Success of prophylactic antiviral therapy for SARS-CoV-2: Predicted critical efficacies and impact of different drug-specific mechanisms of action. PLoS Comput Biol. 17, e1008752 (2021).
We thank J. S. Orange and S. G. Kernie for their contributions to this study.
The work was supported by grants from the NIH: AI121349, NS091263, and NS105699, AI146980 to M.P., from the French ANR NITRODEP (ANR-13-PDOC-0010-01) to C.M. and from the Region Auvergne Rhone Alpes and LABEX ECOFECT (ANR-11-LABX-0048) of Lyon University within the program “Investissements d'Avenir” (ANR-11-IDEX-0007), operated by the French National Research Agency (ANR) to B.H. The Sharon Golub Fund at Columbia University Irving Medical Center (CUIMC).
C.M., A.M., B.H., and M.P. have submitted a provisional on the use of the scFv.
About this article
Cite this article
Mathieu, C., Ferren, M., Harder, O. et al. Single-chain variable fragment antibody constructs neutralize measles virus infection in vitro and in vivo. Cell Mol Immunol (2021). https://doi.org/10.1038/s41423-021-00691-y